Book Appointment
Subscribe to out newsletter today to receive latest news administrate cost effective for tactical data.
Seasoned Medical Oncologist with 15+ years of cancer care experience.
About Dr. Sandip GangulyDr. Sandip Ganguly is a highly respected Medical Oncologist with over 15 years of dedicated experience in cancer treatment. He currently serves as a Consultant Medical Oncologist at Apollo Cancer Hospital in Kolkata. Prior to this, he spent eight years at the Tata Medical Centre, Kolkata, where he gained substantial experience in managing complex cancer cases.
Why Choose 
With his extensive academic background and specialized training, Dr. Sandip Ganguly has emerged as a leading figure in the field of oncology. Throughout his career, he has demonstrated a commitment to delivering personalized care tailored to each patient's unique needs
Our products are certified by reputable organic.
Our products are certified by reputable organic.
DM Medical Oncology from Kidwai Memorial Institute of Oncology, RGUHS Karnataka
Doctor of Medicine (MD), Postgraduate degree in Internal Medicine, from Manipal University.
Bachelor of Medicine and Bachelor of Surgery(MBBS) Graduate degree, from Manipal University, with first class honours in Final Year Part II and distinction in First MBBS, Second MBBS and Final Year Part I
Tan DSW, Felip E, de Castro G, Solomon BJ, Greystoke A, Cho BC, Cobo M, Kim TM, Ganguly S, Carcereny E, Paz-Ares L, Bennouna J, Garassino MC, Schenker M, Kim SW, Brase JC, Bury-Maynard D, Passos VQ, Deudon S, Dharan B, Song Y, Caparica R,Johnson BE. Canakinumab Versus Placebo in Combination With First Line Pembrolizumab Plus Chemotherapy for Advanced Non-Small-Cell Lung Cancer: Results From the CANOPY-1 Trial. J Clin Oncol. 2023 Dec 1:JCO2300980. doi:
10.1200/JCO.23.00980.
Tan D , Felip E, Castro, G, SolomonB, Greystoke A, Cho B, Cobo M, Kim T, Ganguly S, et al. Abstract CT037: Canakinumab in combination with first-line (1L) pembrolizumab plus chemotherapy for advanced non-small cell lung cancer (aNSCLC): Results from the CANOPY-1 phase 3 trial. Cancer Research. 82. CT037-CT037.
10.1158/1538-7445.AM2022-CT037.
Passaro A, Wang J, Wang Y, Lee SH, Melosky B, Shih JY, Wang J, Azuma K, Juan-Vidal O, Cobo M, Felip E, Girard N, Cortot AB, Califano R, Cappuzzo F, Owen S, Popat S, Tan JL, Salinas J, Tomasini P, Gentzler RD, William WN Jr, Reckamp KL, Takahashi T, Ganguly S, Kowalski DM, Bearz A, MacKean M, Barala P, Bourla AB, Girvin A, Greger J, Millington D, Withelder M, Xie J, Sun T, Shah S, Diorio B, Knoblauch RE, Bauml JM, Campelo RG, Cho BC; MARIPOSA-2 Investigators. Amivantamab plus chemotherapy with and without lazertinib in EGFR mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study. Ann Oncol. 2023 Oct 23:S0923-7534(23)04281-3. doi:
10.1016/j.annonc.2023.10.117.
For standing First in the Competitive Examination in Medicine-Thoracic Medicine and Cardiology held in January 2011.
Held in Chennai 2015
A randomized, double-blind, placebo-controlled, phase III study evaluating the efficacy and safety of pembrolizumab plus platinum-based chemotherapy with or without canakinumab as first line therapy for locally advanced or metastatic non-squamous and squamous non-small cell lung cancer subjects
(CANOPY-1)
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-center Study of Durvalumab Monotherapy or in Combination with Bevacizumab as Adjuvant Therapy in Patients With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation
(EMERALD-2)
A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Transarterial Chemoembolization (TACE) in Combination with either Durvalumab Monotherapy or Durvalumab plus Bevacizumab Therapy in Patients with Locoregional Hepatocellular Carcinoma (EMERALD-1))